Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'

被引:30
|
作者
Tan, Xing [1 ]
Johnson, Stuart [2 ,3 ]
机构
[1] Univ Illinois, Chicago, IL USA
[2] Edward Hines Jr VA Hosp, Hines, IL USA
[3] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
关键词
Clostridioides difficile; Clostridium difficile; Fecal microbiota transplant; Recurrence; RECURRENT CLOSTRIDIUM-DIFFICILE; OPEN-LABEL; VANCOMYCIN TAPER; ORAL VANCOMYCIN; DOUBLE-BLIND; FOLLOW-UP; DIARRHEA; FIDAXOMICIN; PREVENTION; RIFAXIMIN;
D O I
10.1016/j.anaerobe.2019.102092
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Despite lack of regulatory approval, fecal microbiota transplantation (FMT) is widely performed to manage C. difficile infection (CDI), particularly recurrent CDI. Herein, we critically review the available randomized controlled trials of FMT and address the following questions: Is FMT better than drug management of recurrent CDI?; Is FMT treatment per se or adjunctive treatment to antibiotics for CDI?; and, Is FMT safe? Finally, we elaborate non-FMT options for the management of recurrent CDI. Although promising, FMT should be reserved for patients who have failed appropriate antibiotic management of recurrent CDI. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页数:6
相关论文
共 50 条